ClinConnect ClinConnect Logo
Search / Trial NCT02240472

Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.

Launched by KAROLINSKA INSTITUTET · Sep 12, 2014

Trial Information

Current as of April 30, 2025

Active, not recruiting

Keywords

Sentinel Node Biopsy, Lymph Node Metastasis, Survival

ClinConnect Summary

This clinical trial is studying whether it is safe for breast cancer patients to skip a surgery called axillary clearance (removal of additional lymph nodes from the armpit) if their sentinel node biopsy shows that 1-2 lymph nodes have larger tumor deposits, known as macrometastasis. The goal is to see if not doing this extra surgery affects patients' survival rates in a significant way over five years. Researchers believe that avoiding this surgery could reduce complications, such as swelling and pain in the arm, while still providing effective treatment for breast cancer.

To be eligible for the trial, patients must have invasive breast cancer but show no signs of cancer spread to the lymph nodes during a physical exam. They should also have a preoperative ultrasound and a pathology report that confirms macrometastasis in 1-2 sentinel lymph nodes. Participants will be randomly assigned to either have the axillary clearance surgery or not. Throughout the study, researchers will monitor important outcomes like survival rates and the recurrence of cancer in the axillary area. This trial includes 3,500 patients and is currently active but not recruiting new participants.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with invasive breast cancer (T1-T3)
  • N0 on palpation
  • Preoperative ultrasound performed
  • Pathology report shows macrometastasis in 1-2 sentinel lymph nodes
  • Patients undergo breast-conserving therapy or mastectomy
  • The patient must have provided oral and written consent
  • Age ≥ 18 years
  • Exclusion Criteria:
  • Metastases outside of the ipsilateral axilla
  • Prior history of invasive breast cancer
  • Pregnancy
  • Bilateral breast cancer if one side meets exclusion criteria
  • Medical contraindication for radiotherapy or systemic treatment
  • Inability to absorb or understand the meaning of the study information; for example, through disability, inadequate language skills or dementia.

About Karolinska Institutet

Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.

Locations

Copenhagen, , Denmark

Odense, , Denmark

Aarhus, , Denmark

Uppsala, , Sweden

Göteborg, , Sweden

Stockholm, , Sweden

Linköping, , Sweden

Aalborg, , Denmark

örebro, , Sweden

Umeå, , Sweden

Uddevalla, , Sweden

Västervik, , Sweden

örebro, , Sweden

Gävle, , Sweden

Viborg, , Denmark

Halmstad, , Sweden

Jönköping, , Sweden

Karlstad, , Sweden

Esbjerg, , Denmark

Aabenraa, , Denmark

Lillebaelt, , Denmark

Randers, , Denmark

Athens, , Greece

Helsingborg, , Sweden

Kalmar, , Sweden

Karlskrona, , Sweden

Kristianstad, , Sweden

Lund, , Sweden

Skövde/Lidköping, , Sweden

Stockholm, , Sweden

Stockholm, , Sweden

Sundsvall, , Sweden

Varberg, , Sweden

Västerås, , Sweden

Patients applied

0 patients applied

Trial Officials

Jana de Boniface, PhD

Principal Investigator

Karolinska Institutet

Jan Frisell, Professor

Study Chair

Karolinska University Hospital

Leif Bergkvist, Professor

Study Chair

Central Hospital Västerås

Yvette Andersson, PhD

Study Chair

Central Hospital Västerås

Lisa Ryden, Professor

Study Chair

Lund University

Malin Sund, Professor

Study Chair

Umeå University Hospital

Olofsson Roger, PhD

Study Chair

Sahlgrenska University Hospital

Johan Ahlgren, PhD

Study Chair

Region Örebro County

Dan Lundstedt, PhD

Study Chair

Sahlgrenska University Hospital

Peer Christiansen, Professor

Principal Investigator

Aarhus University Hospital, Denmark

Tove Tvedskov Filtenborg, MD

Study Chair

Rigshospitalet Copenhagen, Dnmark

Michalis Kontos, PhD

Study Chair

University of Athens

Birgitte Offersen, Professor

Study Chair

University of Aarhus

Thorsten Kühn, Professor

Principal Investigator

Klinikum Esslingen

Toralf Reimer, Professor

Principal Investigator

Universität Rostock

Oreste Gentilini

Principal Investigator

San Raffaele Hospital, Milano

Roland Reitsamer

Principal Investigator

Universitätsklinikum Salzburg

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials